Prolexys HyNet

Prolexys Pharmaceuticals was formed in 2001 with the goal of mapping human protein interactions. This lead to the development of HyNet™, Prolexys's high-throughput (3000-9000 searches per week) automated, LIMS-controlled yeast two-hybrid screening platform.

The Prolexys Human Interactome Database (Prolexys HyNet) is an extensive collection of experimentally determined and verified human protein-protein interactions (PPI’s). It is the largest human PPI database in the world, containing over 120,000 non-redundant human protein interactions covering nearly one half of the human genes in the NCBI RefSeq database. A detailed review of the HyNet methods can be found in the publication:  Plasmodium falciparum interactome in Nature vol.438 (2005), pp 103 – 107.

The Human Interactome Database (PDF Description) will add significant value to state-of-the-art pharmaceutical research programs related to:

  • Target identification
  • Pathway discovery
  • Investigation of disease biology
  • Target discovery


The Prolexys Human Interactome Database is integrated with Pathway Studio pathway analysis software, and is available for purchase through Ariadne.

Features of the HyNet Database

Statistics

  • Over 45% of RefSeq is covered.
  • Comprising of over 120,000 non-redundant human protein interactions.
  • Includes over 11,500 unique human loci.
  • Over 70% of cell signaling pathways members in BioCarta are represented.

Accuracy

  • Large dataset makes it possible to eliminate false positives.
  • Confidence based on redundancy and retest rate.
  • Interactions verified by directed Y2H and mass spectrometry (HySpec™).
  • Confirmation in literature and other public protein interaction datasets.
  • Quality Assurance and Control are part of the HyNet™ Process.

Unique

  • Built from customized cDNA libraries from a wide range of tissue sources.
  • Categorized and annotated by molecular function, cellular components, biological processes.
  • More than 10 times larger than any other public database.
  • The product of three years of process development, production, and bioinformatics analysis.
  • Includes tissue and domain specific interaction knowledge.

Benefits

  • Includes novel interactors in virtually all pathways of interest.
  • Discovers novel kinases, phosphatases, and phosphatase regulatory elements.
  • Provides a more complete look at proteins that populate pathways of interest.
  • Place pathways in the context of the larger view of the human interactome.
  • Discover new possible indications or potential sources of undesired effects.